{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Elevate", "query": { "intervention": "Elevate" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16858, "total_pages": 1686, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Elevate&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T16:43:47.293Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05794958", "title": "Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin Lymphoma", "Large B-cell Lymphoma" ], "interventions": [ { "name": "Axicabtagene Ciloleucel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2023-05-23", "completion_date": "2038-04-01", "has_results": false, "last_update_posted_date": "2025-09-23", "last_synced_at": "2026-09-08T16:43:47.293Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05794958" }, { "nct_id": "NCT02511808", "title": "Adaptive Interventions for Problem Drinkers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Alcohol-Related Disorders", "Alcohol Use Disorders", "Alcohol Drinking", "Alcoholism", "Alcohol Abuse" ], "interventions": [ { "name": "Brief Advice", "type": "BEHAVIORAL" }, { "name": "Motivational Interviewing", "type": "BEHAVIORAL" }, { "name": "Behavioral Self-Control Training", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 164, "start_date": "2015-03", "completion_date": "2019-05", "has_results": false, "last_update_posted_date": "2020-09-11", "last_synced_at": "2026-09-08T16:43:47.293Z", "location_count": 1, "location_summary": "Great Neck, New York", "locations": [ { "city": "Great Neck", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02511808" }, { "nct_id": "NCT03896568", "title": "MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "IDH1 wt Allele", "Recurrent Anaplastic Astrocytoma", "Recurrent Glioblastoma", "Recurrent Gliosarcoma", "Recurrent Malignant Glioma" ], "interventions": [ { "name": "Oncolytic Adenovirus Ad5-DNX-2401", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2019-02-12", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-09-08T16:43:47.293Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03896568" }, { "nct_id": "NCT00569010", "title": "Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "Myelodysplastic Syndrome", "Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Ara-C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2005-12", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2012-08-01", "last_synced_at": "2026-09-08T16:43:47.293Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00569010" }, { "nct_id": "NCT01270724", "title": "Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "CNS Germ Cell Tumor" ], "interventions": [ { "name": "Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nationwide Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 10, "start_date": "2010-08", "completion_date": "2019-12-09", "has_results": true, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-09-08T16:43:47.293Z", "location_count": 5, "location_summary": "Phoenix, Arizona • Los Angeles, California • New York, New York + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01270724" }, { "nct_id": "NCT05695924", "title": "Surgical Evaluation for Upper Extremity Lymphedema (BioBridge)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lymphedema", "Edema" ], "interventions": [ { "name": "BioBridge® Collagen Matrix", "type": "DEVICE" }, { "name": "Vascularized Lymph Node Transfer (VLNT)", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "PROCEDURE" ], "sponsor": "Fibralign Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 60, "start_date": "2023-11-01", "completion_date": "2025-12-01", "has_results": false, "last_update_posted_date": "2025-03-11", "last_synced_at": "2026-09-08T16:43:47.293Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05695924" }, { "nct_id": "NCT06448780", "title": "Dose Optimization of Caffeine for HIE", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypoxic-Ischemic Encephalopathy" ], "interventions": [ { "name": "Caffeine citrate 20 mg/kg", "type": "DRUG" }, { "name": "Caffeine citrate 30 mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "24 Hours", "sex": "ALL", "summary": "Up to 24 Hours" }, "enrollment_count": 16, "start_date": "2024-07-26", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-08T16:43:47.293Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Wilmington, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Wilmington", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06448780" }, { "nct_id": "NCT06417762", "title": "Dime La VerDAD: Verify, Debunk, and Disseminate", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Influenza", "COVID-19", "Communication Research", "Health Behavior", "Respiratory Viral Infection" ], "interventions": [ { "name": "Science Communication Curriculum Cohort 1", "type": "BEHAVIORAL" }, { "name": "Science communication curriculum Cohort 2", "type": "BEHAVIORAL" }, { "name": "Science communication curriculum Cohort 3", "type": "BEHAVIORAL" }, { "name": "Science communication curriculum Cohort 4", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 1400, "start_date": "2024-07-02", "completion_date": "2029-04-01", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-08T16:43:47.293Z", "location_count": 4, "location_summary": "Chicago, Illinois • Iowa City, Iowa • Ann Arbor, Michigan", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06417762" }, { "nct_id": "NCT04549246", "title": "Grid Therapy for Tumors of the Head, Neck, Thorax, Abdomen, Pelvis and Extremities.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Radiation Therapy Complication", "Tumor Neck", "Tumor Abdomen" ], "interventions": [ { "name": "Spatially Fractionated Radiation (GRID) Therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2020-06-18", "completion_date": "2024-06-01", "has_results": false, "last_update_posted_date": "2024-07-30", "last_synced_at": "2026-09-08T16:43:47.293Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04549246" }, { "nct_id": "NCT02452203", "title": "Examining the Effects of Reduced Environmental Stimulation on the Brain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anxiety" ], "interventions": [ { "name": "Floating", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Laureate Institute for Brain Research, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 56, "start_date": "2015-05-01", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2020-09-22", "last_synced_at": "2026-09-08T16:43:47.293Z", "location_count": 1, "location_summary": "Tulsa, Oklahoma", "locations": [ { "city": "Tulsa", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT02452203" } ] }